This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

BAY 2927088, which combines inhibition of HER2 (including exon 20 insertions and point mutations) with blockade of EGFR, both mutations that are seen in NSCLC tumours. The oral drug was awarded ...

322-57_322-8del in PAX3), exon skipping and intron retention (c.6087-3T > G in PTPRQ) and shortening of exon (c.164+5G > A in USH1G). Our study showed that the cryptic, noncanonical splice site ...

For unaffected individuals, the 20-point ... of a mutation; results from other large unselected series were also taken into account.12 13 The new scores in MSS3 were modelled by upward adjustment of 1 ...

1 According to the 8 th edition of IASLC guidelines.

If you're interested in exploring more stocks under $20 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Stocks under $20 offer investors and ...

Among patients with ESR1 mutations, the median progression-free ... 3 trial of patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer who had disease progression ...

Breast cancer subtyping in this study was performed based on the consensus of St. Gallen international experts that divided BC into the following four subtypes: luminal A (ER and/or PR-positive, ...

Specifically, the combo is approved in Europe for patients with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R (L858R) substitution mutations. Earlier this ...

The phone has immense capabilities and offers dynamic features. The best take is the camera and the ease of doing anything you want.